These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 22850772)
21. Why doctors should worry about preemption. Curfman GD; Morrissey S; Drazen JM N Engl J Med; 2008 Jul; 359(1):1-3. PubMed ID: 18596269 [No Abstract] [Full Text] [Related]
22. Safe drugs and the cost of good intentions. Eichler HG; Abadie E; Raine JM; Salmonson T N Engl J Med; 2009 Apr; 360(14):1378-80. PubMed ID: 19339718 [No Abstract] [Full Text] [Related]
23. Pharmaceuticals and medical devices: FDA oversight. ; Berry MD Issue Brief Health Policy Track Serv; 2012 Jan; ():1-86. PubMed ID: 22403845 [No Abstract] [Full Text] [Related]
24. FDA reform signed into law. Food and Drug Administration. James JS AIDS Treat News; 1997 Dec; (No 284):6-7. PubMed ID: 11364915 [TBL] [Abstract][Full Text] [Related]
25. PDUFA VI: It Is Time to Unleash the Full Potential of Model-Informed Drug Development. Jain L; Mehrotra N; Wenning L; Sinha V CPT Pharmacometrics Syst Pharmacol; 2019 Jan; 8(1):5-8. PubMed ID: 30370642 [No Abstract] [Full Text] [Related]
26. Speed, Safety, and Industry Funding - From PDUFA I to PDUFA VI. Darrow JJ; Avorn J; Kesselheim AS N Engl J Med; 2017 Dec; 377(23):2278-2286. PubMed ID: 29211663 [No Abstract] [Full Text] [Related]
27. Drug marketing exclusivity under United States and European Union law. Junod V Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347 [No Abstract] [Full Text] [Related]
28. The Prescription Drug User Fee Act of 1992: speeding up the drug approval process. Bierut MB Healthspan; 1992 Dec; 9(11):12-4. PubMed ID: 10123552 [No Abstract] [Full Text] [Related]
32. The challenges of globalization in pharmaceutical law--is an international drug approval system modeled after the European system worth considering? Purnhagen KP Food Drug Law J; 2008; 63(3):623-45. PubMed ID: 19031663 [No Abstract] [Full Text] [Related]
33. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars. Gitter DM Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759 [No Abstract] [Full Text] [Related]
34. Branded drug reformulation: the next brand vs. generic antitrust battleground. Amoresano GV Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032 [No Abstract] [Full Text] [Related]
35. 1992 Le Tourneau Award. Problems with pharmaceutical regulation in the United States. Drug lag and orphan drugs. Henry V J Leg Med; 1993 Dec; 14(4):617-39. PubMed ID: 8308452 [No Abstract] [Full Text] [Related]
36. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill. Ochs A Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540 [No Abstract] [Full Text] [Related]
37. Takings issues in the approval of generic biologics. Yoo JC Food Drug Law J; 2005; 60(1):33-43. PubMed ID: 15940853 [No Abstract] [Full Text] [Related]
38. Realizing two-tiered innovation policy through drug regulation. Ridgway WE Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807 [No Abstract] [Full Text] [Related]
39. A strike against preemption. Nat Biotechnol; 2009 May; 27(5):397. PubMed ID: 19430422 [TBL] [Abstract][Full Text] [Related]
40. FDA and drug safety: new Tufts study challenges critics of the Prescription Drug User Fee Act. Lee R J Law Med Ethics; 2006; 34(1):131-4. PubMed ID: 16489994 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]